-
2025-522642-44-00
4
2026-03-18
CHRONIC SPONTANEOUS URTICARIA
-
2025-521035-37-00
5
2026-03-02
Immune system diseases
-
2025-522029-37-00
5
2026-02-27
Large B-cell Lymphoma
-
2024-516411-24-00
5
2026-02-25
Insomnia Disorder
-
2025-521124-29-00
10
2026-02-13
Non-Small Cell Lung Cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-522370-36-00
4
2026-02-02
Moderate to Severe Atopic Dermatitis
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-519820-26-00
4
2026-01-22
Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-514003-33-00
5
2025-12-29
Patients with clinically diagnosed lichen sclerosus of the vulva.
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-512503-39-00
6
2025-12-19
Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-520831-18-00
4
2025-12-12
Primary Sjogren’s Disease
-
2024-512904-21-00
4
2025-12-10
Migraine
-
2024-520164-33-00
5
2025-12-09
Non-Small Cell Lung Cancer
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease